The global palonosetron market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The market is driven by factors such as increasing incidence of chemotherapy-induced nausea and vomiting (CINV) in adults and children, rising prevalence of cancer globally, and increasing number of cancer patients undergoing chemotherapy treatment.
The injection 0.25 mg/5 mL segment accounted for the largest share in the global palonosetron market in 2018 owing to its high efficacy rate and low cost per dose. The injection 20 mcg/kg (max 1.5 mg) segment is expected to grow at a higher CAGR during the forecast period due to its high efficacy rate and low cost per dose compared with other dosage forms such as tablets or oral solution.
North America accounted for the largest share in the global palonosetron market in 2018 due to increased awareness about CINV among healthcare professionals, rising prevalence of cancer cases, availability of reimbursement policies for antiemetics drugs by insurance companies, and presence of major players operating across this region such as Allergan plc., Merck & Co., Inc, Pfizer Inc, GlaxoSmithKline plc., Novartis AG, AstraZeneca PLC., Eli Lilly & Company Ltd, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Incorporated among others.
-Palonosetron is a 5HT3 receptor antagonist that is used to prevent nausea and vomiting caused by chemotherapy.
-In 2013, it was the most prescribed antiemetic in the US with over 1 million prescriptions written.
Industry Growth Insights published a new data on “Palonosetron Market”. The research report is titled “Palonosetron Market research by Types (Injection 0.25 mg/5 mL, Injection 20 mcg/kg (max 1.5 mg)), By Applications (Adults, Children), By Players/Companies Helsinn Therapeutics, Teva, Dr. Reddys Laboratories, Cipla, Pfizer, Sandoz, Aurobindo, Sagent Pharmaceuticals, Fresenius Kabi, Qilu Pharmaceutical, Jiangsu Aosaikang Pharmaceutical, Sichuan Hairong Pharmaceutical, Exela Pharma”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Palonosetron Market Research Report
By Type
Injection 0.25 mg/5 mL, Injection 20 mcg/kg (max 1.5 mg)
By Application
Adults, Children
By Companies
Helsinn Therapeutics, Teva, Dr. Reddys Laboratories, Cipla, Pfizer, Sandoz, Aurobindo, Sagent Pharmaceuticals, Fresenius Kabi, Qilu Pharmaceutical, Jiangsu Aosaikang Pharmaceutical, Sichuan Hairong Pharmaceutical, Exela Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
231
Number of Tables & Figures
162
Customization Available
Yes, the report can be customized as per your need.
Global Palonosetron Market Report Segments:
The global Palonosetron market is segmented on the basis of:
Types
Injection 0.25 mg/5 mL, Injection 20 mcg/kg (max 1.5 mg)
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Adults, Children
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Helsinn Therapeutics
- Teva
- Dr. Reddys Laboratories
- Cipla
- Pfizer
- Sandoz
- Aurobindo
- Sagent Pharmaceuticals
- Fresenius Kabi
- Qilu Pharmaceutical
- Jiangsu Aosaikang Pharmaceutical
- Sichuan Hairong Pharmaceutical
- Exela Pharma
Highlights of The Palonosetron Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Injection 0.25 mg/5 mL
- Injection 20 mcg/kg (max 1.5 mg)
- By Application:
- Adults
- Children
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Palonosetron Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Palonosetron is a medication used to treat nausea and vomiting. It is a type of anti-nausea drug called an 5HT3 receptor antagonist. Palonosetron works by blocking the action of serotonin in the brain, which reduces nausea and vomiting.
Some of the major players in the palonosetron market are Helsinn Therapeutics, Teva, Dr. Reddys Laboratories, Cipla, Pfizer, Sandoz, Aurobindo, Sagent Pharmaceuticals, Fresenius Kabi, Qilu Pharmaceutical, Jiangsu Aosaikang Pharmaceutical, Sichuan Hairong Pharmaceutical, Exela Pharma.
The palonosetron market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Palonosetron Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Palonosetron Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Palonosetron Market - Supply Chain
4.5. Global Palonosetron Market Forecast
4.5.1. Palonosetron Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Palonosetron Market Size (000 Units) and Y-o-Y Growth
4.5.3. Palonosetron Market Absolute $ Opportunity
5. Global Palonosetron Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Palonosetron Market Size and Volume Forecast by Type
5.3.1. Injection 0.25 mg/5 mL
5.3.2. Injection 20 mcg/kg (max 1.5 mg)
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Palonosetron Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Palonosetron Market Size and Volume Forecast by Application
6.3.1. Adults
6.3.2. Children
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Palonosetron Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Palonosetron Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Palonosetron Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Palonosetron Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Palonosetron Demand Share Forecast, 2019-2029
9. North America Palonosetron Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Palonosetron Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Palonosetron Market Size and Volume Forecast by Application
9.4.1. Adults
9.4.2. Children
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Palonosetron Market Size and Volume Forecast by Type
9.7.1. Injection 0.25 mg/5 mL
9.7.2. Injection 20 mcg/kg (max 1.5 mg)
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Palonosetron Demand Share Forecast, 2019-2029
10. Latin America Palonosetron Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Palonosetron Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Palonosetron Market Size and Volume Forecast by Application
10.4.1. Adults
10.4.2. Children
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Palonosetron Market Size and Volume Forecast by Type
10.7.1. Injection 0.25 mg/5 mL
10.7.2. Injection 20 mcg/kg (max 1.5 mg)
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Palonosetron Demand Share Forecast, 2019-2029
11. Europe Palonosetron Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Palonosetron Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Palonosetron Market Size and Volume Forecast by Application
11.4.1. Adults
11.4.2. Children
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Palonosetron Market Size and Volume Forecast by Type
11.7.1. Injection 0.25 mg/5 mL
11.7.2. Injection 20 mcg/kg (max 1.5 mg)
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Palonosetron Demand Share, 2019-2029
12. Asia Pacific Palonosetron Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Palonosetron Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Palonosetron Market Size and Volume Forecast by Application
12.4.1. Adults
12.4.2. Children
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Palonosetron Market Size and Volume Forecast by Type
12.7.1. Injection 0.25 mg/5 mL
12.7.2. Injection 20 mcg/kg (max 1.5 mg)
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Palonosetron Demand Share, 2019-2029
13. Middle East & Africa Palonosetron Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Palonosetron Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Palonosetron Market Size and Volume Forecast by Application
13.4.1. Adults
13.4.2. Children
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Palonosetron Market Size and Volume Forecast by Type
13.7.1. Injection 0.25 mg/5 mL
13.7.2. Injection 20 mcg/kg (max 1.5 mg)
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Palonosetron Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Palonosetron Market: Market Share Analysis
14.2. Palonosetron Distributors and Customers
14.3. Palonosetron Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Helsinn Therapeutics
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Teva
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Dr. Reddys Laboratories
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Cipla
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Pfizer
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Sandoz
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Aurobindo
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Sagent Pharmaceuticals
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Fresenius Kabi
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Qilu Pharmaceutical
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Jiangsu Aosaikang Pharmaceutical
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Sichuan Hairong Pharmaceutical
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Exela Pharma
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
